Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation

by | Aug 10, 2023

 Clostridioides difficile infection (CDI) is an opportunistic infection of the gastrointestinal tract, commonly associated with antibiotic administration, that afflicts almost 500 000 people yearly only in the United States. CDI incidence and recurrence is increased in inflammatory bowel disease (IBD) patients. Omilancor is an oral, once daily, first-in-class, gut-restricted, immunoregulatory therapeutic in clinical development for the treatment of IBD.

Read More

Recent Releases

Press Release
NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity

NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity

Download Press Release New results affirm omilancor’s ability to safely reverse colonic regulatory T-cell (Treg) depletion and mitochondrial dysfunction in severe UC patients which defines a core subset of patients traditionally refractory to existing approved IBD...

Read More

Press Release
The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science

The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science

Download Press Release TITAN-X Precision Medicine A.I. Platform identifies therapeutic targets and successfully fueled development of expansible pipelines with leading therapeutic assets in Phase 1-3 clinical testing Integrates A.I., bioinformatics and advanced...

Read More

Press Release
NIMML Institute to Present Novel Clinical and Translational Data of Omilancor in Ulcerative Colitis Patients at Digestive Disease Week 2025

NIMML Institute to Present Novel Clinical and Translational Data of Omilancor in Ulcerative Colitis Patients at Digestive Disease Week 2025

The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for inflammatory and autoimmune diseases, will present results from two novel studies for omilancor, a once-daily, oral, best- and first-in-class therapy in Phase 3 clinical development for ulcerative colitis (“UC”) and Phase 2 for Crohn’s disease, at  Digestive Disease Week 2025. DDW 2025 will be held at the San Diego Convention Center from May 3-6, 2025.

Read More